Melanoma-associated retinopathy treated with ipilimumab therapy

Dermatology

Volumn 227, Issue 2, 2013, Pages 146-149

  Audemard, A ^a   De Raucourt, S ^b   Miocque, S ^c   Comoz, F ^d   Giraud, J M ^e   Dreno, B ^f   Bienvenu, B ^a   Rogerie, M J ^g   Dompmartin, A ^b  

^a Departments of Internal Medicine   (France)

^b Departments of Dermatology   (United States)

^c Departments of Ophthalmology   (United States)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e University of Paris Descartes   (France)

^f HÔTEL DIEU   (France)

^g Clinique Saint Jean   (France)

Author keywords

Autoimmunity; Cancer; Melanoma Ipilimumab; Melanoma associated retinopathy

Indexed keywords

CORTICOSTEROID; DACARBAZINE; FLUORODEOXYGLUCOSE; IPILIMUMAB; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

AGED; ARTICLE; BETA RHYTHM; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CASE REPORT; CHOROID MELANOMA; CORTICOSTEROID THERAPY; CUTANEOUS MELANOMA; DRUG TREATMENT FAILURE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; HYPOPIGMENTATION; LUNG NODULE; LYMPH NODE DISSECTION; MEDIASTINUM LYMPH NODE; MELANOMA ASSOCIATED RETINOPATHY; METASTATIC MELANOMA; OPHTHALMOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETINOPATHY; SIDE EFFECT; SUBCUTANEOUS NODULE; VISUAL ACUITY; VITILIGO; CANCER PATIENT; CANCER SURGERY; LYMPH NODE METASTASIS; MELANOMA; TUMOR VOLUME;

AGED; ANTIBODIES, MONOCLONAL; AUTOIMMUNITY; DIAGNOSIS, DIFFERENTIAL; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; MELANOMA; PARANEOPLASTIC SYNDROMES, OCULAR; SKIN NEOPLASMS;

EID: 84888248267     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000353408     Document Type: Article

References (19)

1. Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS; MDX010-20 Investigators: Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119: 1675-1682.
2. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, Bergmann T, Bockmeyer CL, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Keller U, Klein C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Heinzerling LM: The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8:e53745.
3. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-6688.
4. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043-6053.
5. Maire C, Vercambre-Darras S, Devos P, D'Herbomez M, Dubucquoi S, Mortier L: Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort. J Eur Acad Dermatol Venereol 2013; 1: 92-96.
6. Nieuwendijk TJ, Hooymans JM: Paraneoplastic vitelliform retinopathy associated with metastatic choroidal melanoma. Eye 2007; 21: 1436-1437.
7. Pföhler C, Haus A, Palmowski A, Ugurel S, Ruprecht KW, Thirkill CE, Tilgen W, Reinhold U: Melanoma-associated retinopathy: high frequency of subclinical findings in patients with melanoma. Br J Dermatol 2003; 149: 74-78.
8. Keltner JL, Thirkill CE, Yip PT: Clinical and immunologic characteristics of melanomaassociated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001; 21: 173-187.
9. Gittinger JW Jr, Smith TW: Cutaneous melanoma-associated paraneoplastic retinopathy: histopathologic observations. Am J Ophthalmol 1999; 127: 612-614.
10. Arnheiter H: Evolutionary biology. Eyes viewed from the skin. Nature 1998; 391: 632-633.
11. Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR: Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 1993; 34: 91-100.
12. Bazhin AV, Schadendorf D, Willner N, De Smet C, Heinzelmann A, Tikhomirova NK, Umansky V, Philippov PP, Eichmüller SB: Photoreceptor proteins as cancer-retina antigens. Int J Cancer 2007; 120: 1268-1276.
13. Kondo M, Sanuki R, Ueno S, Nishizawa Y, Hashimoto N, Ohguro H, Yamamoto S, Machida S, Terasaki H, Adamus G, Furukawa T: Identification of autoantibodies against TRPM1 in patients with paraneoplastic retinopathy associated with ON bipolar cell dysfunction. PLoS One 2011; 6:e19911.
14. Ladewig G, Reinhold U, Thirkill CE, Kerber A, Tilgen W, Pföhler C: Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. Br J Dermatol 2005; 152: 931-938.
15. Boeck K, Hofmann S, Klopfer M, Ian U, Schmidt T, Engst R, Thirkill CE, Ring J: Melanoma-associated paraneoplastic retinopathy: case report and review of the literature. Br J Dermatol 1997; 137: 457-460.
16. Subhadra C, Dudek AZ, Rath PP, Lee MS: Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol 2008; 28: 23-26.
17. Powell SF, Dudek AZ: Treatment of melanoma-associated retinopathy. Curr Treat Options Neurol 2010; 12: 54-63.
18. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L: Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7: 95-106.
19. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.